Please login to the form below

Not currently logged in
Email:
Password:

Pfizer sued for off-label Lipitor marketing

A former Pfizer official accuses the company of illegally boosting sales of its top-selling drug Lipitor through misleading medical educational programmes for doctors

A former Pfizer official has accused the company of illegally boosting sales of its top-selling drug Lipitor (atorvastatin) through misleading medical educational programmes for doctors.

The allegations against Pfizer concern continuing medical-education programmes for doctors, which are often sales pitches for "off-label" uses of drugs.

Dr Jesse Polansky, claims that the educational campaign was a key part of a marketing strategy which persuaded thousands of doctors to prescribe Lipitor for millions of patients who did not need the drug and could have been harmed as a result.

The lawsuit was filed in US District Court for the Eastern District of New York in February 2004. Pfizer was served a copy of the suit on 19 December, according to Dr Polansky's lawyer, Steve Berman of Hagens Berman Sobol Shapiro.

Pfizer said in a statement: "We believe this case has no meritÖPfizer does not condone the off-label promotion of our products. We believe that our sales and marketing practices are solely based on our prescription information as approved by the FDA."

Polansky was Pfizer's director of outcomes management strategies from 2001 to 2003. As part of his role, he reviewed some of the marketing materials for Lipitor and other Pifzer products.

Polansky claims Pfizer fired him when he complained about marketing he considered to be improper. He now works as the senior medical officer for Medicare in a unit that investigates fraud and abuse at the big government health insurer.

The suit seeks compensation for Polansky as a whistleblower. Federal laws in the US mean he could win a share of money recovered for any overpayments made by federal health-insurance programmes.

The lipid-lowering drug Lipitor is the world's biggest-selling treatment and racked up FY06 sales of USD 13.6bn, according to IMS Health data.

20th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics